{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:19:37Z","timestamp":1778948377580,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.leukres.2023.107078","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T05:27:34Z","timestamp":1681968454000},"page":"107078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Antibody-drug conjugate [ADC] treatment of leukaemia"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4750-6538","authenticated-orcid":false,"given":"Hassan Tawhid","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9825","key":"10.1016\/j.leukres.2023.107078_bib1","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.leukres.2023.107078_bib2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"32","key":"10.1016\/j.leukres.2023.107078_bib3","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107078_bib4","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC\u2010GIMEMA AML\u201019 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107078_bib5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3324\/haematol.2016.141937","article-title":"Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg\/m2 with 6 mg\/m2 in the NCRI AML17 Trial","volume":"101","author":"Burnett","year":"2016","journal-title":"Haematologia"},{"key":"10.1016\/j.leukres.2023.107078_bib6","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2023.107078_bib7","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1634\/theoncologist.2019-0025","article-title":"The EMA review of Mylotarg for the treatment of Acute myeloid leukaemia","volume":"24","author":"Ali","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2023.107078_bib8","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/ajh.23795","article-title":"Gemtuzumab ozogamicin with fludarabine, cytarabine, and (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia","volume":"89","author":"Borthakur","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"supplement 1","key":"10.1016\/j.leukres.2023.107078_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2019-126014","article-title":"Fludarabine, cytarabine, G-CSF and gemtuzumab ozogamicin (FLAG-GO) regimen results in better molecular response and relapse-free survival in core binding factor acute myeloid leukemia than FLAG and idarubicin (FLAG-Ida)","volume":"134","author":"Borthakur","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107078_bib10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.19.01406","article-title":"Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study","volume":"38","author":"Schlenk","year":"2020","journal-title":"J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107078_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologia"},{"key":"10.1016\/j.leukres.2023.107078_bib12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2019003471","article-title":"Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia","volume":"135","author":"Fournier","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107078_bib13","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/j.leukres.2009.12.006","article-title":"Complete molecular remission in refractory acute myeloid leukemia with MLL\/AF9 treated with gemtuzumab ozogamicin","volume":"34","author":"Asano","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2023.107078_bib14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood.V126.23.799.799","article-title":"Treatment of 11q23\/MLL + AML with gemtuzumab ozogamicin: Results from the randomized phase III children\u2019s oncology group trial AAML0531","volume":"126","author":"Pollard","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2023.107078_bib15","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1002\/cncr.28334","article-title":"Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia","volume":"15","author":"O\u2019Hear","year":"2013","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2023.107078_bib16","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2023.107078_bib17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.leukres.2023.107078_bib18","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2023.107078_bib19","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2147\/DDDT.S150317","article-title":"Inotuzumab ozogamicin: a CD22 mAb\u2013drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"12","author":"Yurkiewicz","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"issue":"8","key":"10.1016\/j.leukres.2023.107078_bib20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard care for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.leukres.2023.107078_bib21","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long\u2010term survival follow\u2010up from the randomized, phase 3 INO\u2010VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2023.107078_bib22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","article-title":"Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini\u2013Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome\u2013Negative Acute Lymphoblastic Leukemia","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol."},{"issue":"20","key":"10.1016\/j.leukres.2023.107078_bib23","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1002\/cncr.31720","article-title":"Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab is highly effective in patients with philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.leukres.2023.107078_bib24","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood.2020007848","article-title":"A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study)","volume":"137","author":"Brivio","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2023.107078_bib25","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"10.1016\/j.leukres.2023.107078_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-020-01004-y","article-title":"Moxetumomab pasdudotox in heavily pre-treated patients with relapsed\/refractory Hairy Cell leukaemia (HCL): long-term follow up from the pivotal study","volume":"14","author":"Kreitman","year":"2021","journal-title":"J. Haematol. Oncol."},{"key":"10.1016\/j.leukres.2023.107078_bib27","doi-asserted-by":"crossref","first-page":"1068981","DOI":"10.3389\/fonc.2022.1068981","article-title":"Novel targeted treatments in hairy cell and other hairy cell-like disorders leukaemia","volume":"12","author":"Maitre","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2023.107078_bib28","unstructured":"N. Daver, P. Montesinos, A. Aribi, et al. Broad activity for the Pivekimab Sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in high-risk patients with relapsed\/refractory acute myeloid leukemia (AML), Abstract #62, in: Presented during the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana, held December 10\u201313, 2022."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:09Z","timestamp":1758935049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623000632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":28,"alternative-id":["S0145212623000632"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107078","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-drug conjugate [ADC] treatment of leukaemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107078"}}